

Index

a

- A431 carcinoma cells 151–155
- acid phosphatases (AcPs) 209
- Amphotericin B (AMB) 294
- antibacterial (fluoro)quinolones
 - HIV integrase inhibitor elvitegravir 245–246
 - interactions with metal ions 241
 - ruthenium-quinolone complexAFM experiments 242
 - β -ketocarboxylate functionality 244
 - and cinoxacin 243
 - cysteine cathepsins 244
 - cytotoxicity assays 243
 - human serum albumin (HSA) 243
 - immunoglobulins 245
 - nalidixic acid 243, 245
 - pharmacological characterization 245
 - thionated quinolone 244
- antibacterial 8-hydroxyquinolines
 - 2,9-dimethyl-1,10-phenanthroline 247
 - mode-of-action 246–247
 - organoruthenium-clioquinol complex 247
- anticancer agents
 - antimetastatic effects, of NAMI 165
 - biological reductants 161
 - biotinylated Ru(arene) complex 172
 - delivery strategies 162
 - enhanced permeability and retention effect 163
 - KP1019 164
 - levonorgestrel 171
 - ligand exchange rates 161
 - macromolecular carrier systems
 - dendrimers 169
 - organometallic compounds 166–168
 - polymers and liposomes 168–169
 - metallaprisms, metallarectangles and metallacycles 174
 - NKP-1339 164
 - organometallic hormone-receptor targeting agents 170
 - peptides 173–174
 - protein binding 163–166
 - RAPTA analogues 172
 - RAPTA-C 169
 - steroid hormones 170
 - structures of 162
 - vitamins 171
- anticancer compounds
 - acid phosphatases (AcPs) 209
 - cellular uptake 204–205
 - cisplatin, side-effects and acquired drug resistance 201
 - DNA and DNA-related cellular targets
 - glutathione (GSH) levels 205
 - KP1019 activity 206
 - PARP-1 (Poly(ADP-ribose) polymerase-1) 206
 - endosomal/lysosomal system and ER-Golgi network 207
 - glycolytic pathways 209–211
 - macromolecular ruthenium-conjugates
 - EPR effect 212
 - RAPTA-C polymeric micelles 211
 - RuPMC 214
 - NAMI-A and NAMI-A-type complexes 203
 - Ru(η^6 -arene) scaffold 203
 - targeting signaling pathways 207
 - thioredoxin reductase (TrxR) 207

- anticancer compounds (*contd.*)
 titanocene dichloride and budotitane 202
 transition metals 201
- antifungal activity investigations
 aromatic and heteroaromatic ligands 305–306
 arylazo 310–312
 catecholamine 310–312
 chalcones 310
 cytotoxicity tests 313
 dithio-naphthyl-benzamide 310–312
 organophosphorated ligand 310–312
 pathogenic fungi species 300, 304–305
 Schiff bases 307–309
 structure-activity relationship 312
 thiosemicarbazones 309
- antimalarial 4-aminoquinolines
 mechanism of action 248–249
 metallocene analogues, of chloroquine 249–252
- aromatic and heteroaromatic ligands 305–306
- artificial water oxidation 49, 50
- arylazo 310–312
- b**
- bidentate 307–309
 bridging ligands 7
- binuclear mixed-metal complexes 73
 1,4-bis(pyrid-3-yl)benzene (bpb) 57
- bioactive azole ligands 310–312
- bioactive ligand scaffolds 284–285
- bioactive sites
 Pt(II) chemotherapeutic agents 140–141
 Rh(III) complexes 141, 142
 Ru(II) metal centre 149–150
 and Co(III) metal centres 151
 and Cu, 150–151 in nanomedicine 152–155
 Pt(II) bioactive sites 143–146
 Rh(III) bioactive sites 147
 and V(IV) metal centres 151
- 2,2'-bipyridine ligands 69
- Brewer, K.J.
 award-recognized educator 4
 collaboration with Winkel, Brenda 16–18
 early years 4–6
- graduate studies and Clemson University 6–11
- legacy 20
- mentor and role model 4
- photochemical H₂ production 18–19
- postdoctoral research and the University of California 11–12
- professional career 19–20
- publications per year from 1985–2015 4
- study of Metal-DNA interactions 16–18
- Virginia Tech 15–16
- Washington State University 13–15
- [(bpy)₂Ru(bpy-4-CH₃,4'-CONHCH₂(4-py)Co(dmgbF₂)₂(OH₂)](PF₆)₂ 75
- [(bpy)₂Ru(bpy-4-CH₃,4'-CONH(4-py)Co(dmgbF₂)₂(OH₂)](PF₆)₂ 75
- c**
- Capillary zone electrophoresis (CZE)-ICP-MS experiments 243
- catecholamine 310–312
- cathepsin B 209
- chemistry of ruthenium(II) and (III) 31, 36
- cisplatin 223
- Co(III) dihydride 9
- [Co(dmgbH)₂(H₂O)₂] 72
- cobaloxime catalyst 68
- cobalt(II)-polypyridyl catalysts 69
- cobalt(III)-hydride 69
- coordination chemistry 20
 element 25–26
 stereochemistry and common oxidation states *see* stereochemistry and common oxidation states
- cross metathesis reaction 33
- cyclometallated systems 228
- cytochrome c₃-viologen-ruthenium(II) triad complex 78
- cytotoxic organoruthenium complexes 285
- d**
- dendrimers 169
- Dewar–Chatt–Duncanson model 27
- dichloro(*p*-cymene)ruthenium(II) dimer 28
- dichlorofluorescein-diacetate (DCFH-DA) 187

- diffusion theory 124
 4,4'-dimethyl-2,2'-bipyridine ligand 69
 dinuclear bis-(-diketones and pentadithiocarbamate ligands 300, 304, 305
 dinuclear ruthenium dithiocarbamate (DTCB) 305
 dinuclear, trinuclear and tetranuclear ruthenium polydentate polypyridil ligands 300, 304, 305
 dithio-naphtyl-benzamide 310–312
 DNA binding, ruthenium complexes
 biological consequences
 antimicrobial activity 191
 cellular uptake experiments 190
 DCFH-DA 187
 FACS analysis 189
 fluorometric assay 187
 H3K56A mutant 189
 KP1019 187
 NAMI-A 190
 platinum complexes' abilities 187
 prokaryotes and eukaryotes 190
 intercalation 184–185
 irreversible covalent binding 182–184
 noncovalent binding interactions 185–186
 topoisomerases and telomerase
 COMET assays 195
 DNA replication 192
 eukaryotes 195
 gel electrophoresis 193
 human genome sequence analysis 196
 in vitro DNA binding and viscosity assays 194
 in vitro plasmid relaxation assays 193
 KP1019 and KP418 193
 DNA targeting/binding modes, of small molecules 222–223
 cellular uptake and localisation 231–232
 cyclometalated ligands 230
 cyclometalated systems 228–231
 dinuclear complexes 228
 intercalation 223
 metal complexes 223–224
 mononuclear complexes 226–228
 non-canonical DNA structures 221
 [Ru(bpy)₂(dppz)]²⁺ and DNA light switch effect 224–226
- e**
 emerging infectious diseases (EID) 293
 energy issue and energy 45–46
 enhanced permeability and retention (EPR) 164, 211, 284
 [Et₃NH]BF₄ 71
- f**
 [FeFe] and [NiFe]-hydrogenase 78
 ferrocifen 170
 fluorescence-activated cell sorting (FACS) analysis 189
 fluorometric assay 187
- g**
 greenhouse gases 67
- h**
 heptacoordinated Ru intermediates 56–57
 heterotrimetallic
 di-ruthenium-mono-palladium complexes 300, 304, 305
 high valent Mn-O intermediate 49
 higher oxidation states of ruthenium 36–37
 Human genome sequence analysis 196
 human serum albumin (HSA) 243
 hydridotris(pyrazolyl)borate 310–312
 hydrogen evolution catalyst (HEC) 71, 77
 hydrogenases, with ruthenium(II) complexes 77–84
- i**
 Invasive Fungal Infections (IFI) 294
 [Ir(tpp)Cl₃] 14
 Ir(III) complex [Ir(dpp)₂Cl₂]⁺ 11
- k**
 KP1019/NKP-1339
 activation by reduction 277–278
 clinical development 276
 clinical studies and perspectives 281
 KP1019-loaded micelle-forming PEGylated polymers 276
 mode of action 278–281

- KP1019/NKP-1339 (*contd.*)
 poly(lactic acid) nanoparticles 276
 tumor targeting mediated by plasma proteins 276–277
- I**
 levonorgestrel 171
 ligand photosubstitution reactions with ruthenium compounds
 caging and uncaging biologically active ligands 92–96
 caging cytotoxic ruthenium complexes with organic ligands 96–100
 low energy photosubstitution, *see* low energy photosubstitution
 metal-ligand antibonding e_g orbital 91
 photodynamic therapy (PDT) 91
 light-driven hydrogen (H_2) production 77
 low energy photosubstitution
 phototherapeutic window 100
 Ru photophysics 100–105
 TPA photosubstitution 109–110
 triplet-triplet annihilation upconversion 105–106
 upconverting nanoparticles 106–109
 low valent ruthenium 32
- m**
 macrocyclic tetradentate ligands 11
 metal-to-ligand charge transfer (MLCT)
 electronic spectra and NO-sensor measurements 258
 HOMO and LUMO energies 259
 tetraazamacrocyclic ligand chelator 259
 metronomic chemotherapy 131
 Meyer's blue dimer 53, 54
 mixed metal Ru(II)-Fe(II) bimetallic and tetrametallic complexes 10
 Mixed-Metal/Supramolecular Complexes 139–156
 mixed-valence manganese μ -oxo dimers 12
 mono- or polydentate ligand scaffolds 282
 monodentate bridging ligands 7
 monometallic and bimetallic Fe(II) cyano complexes 10
 Monte Carlo methods 124
 multimetallic complexes 3, 14, 15
 $[(\mu\text{-pdt})Fe_2(CO)_5(PPh_2(C_6H_4CCbpy))Ru(bpy)_2]^{2+}$ 81
- n**
 NAMI-A
 antimetastatic activity 274
 biotransformation 273
 chemical properties 273
 clinical studies and perspectives 275–276
 mode of action 274–275
 [NiFe]-hydrogenases 83
 [NiFeSe]-hydrogenase 78
 nitric oxide synthase (NOS) pathway 207
 nitrogen oxide derivative-ruthenium complexes
 metal-to-ligand charge transfer (MLCT)
 electronic spectra and NO-sensor measurements 258
 HOMO and LUMO energies 259
 quantum yield and LUMO energy 261
 tetraazamacrocyclic ligand chelator, 259nitrosyl ruthenium complexes
 binuclear systems 261
 clinical application 263
 molecular orbital calculations 265
 zinc-phthalocyanine 263
 photochemical pathways 258
 photovoltarelation 265–268
N,N-chelate ethylenediamine 282
- o**
 organophosphorated ligand 310–312
 organoruthenium(II)
 compounds/bioactive ligand scaffolds 284–285
 cytotoxic organoruthenium complexes 285
 enhanced permeability and retention 284
 hydrolysis 283
 mono- or polydentate ligand scaffolds 282
N,N-chelate ethylenediamine 282
 piano-stool complexes 282
 RAPTA-C 282, 283
 RM175 282
 Sadler-type compounds 283

- Os(II)-based antenna complexes 14
 oxo-centered trinuclear ruthenium(III)
 acetate 34
- P**
- PARP-1 (Poly(ADP-ribose) polymerase-1)
 206
- pathogenic fungi species 300, 304–305
- pentaammineruthenium(III) complexes
 272
- Petersen, J.D. 7
- P-glycoprotein 278
- phenantroline 305–306
- phenazine 305–306
- phosphorescence lifetime imaging
 microscopy (PLIM) 231
- photo-stability 128
- photobleaching 125, 131
- photocatalyst 18
- photochemical H₂ production 18, 19
- photodynamic therapy (PDT) 3, 18, 91
 bioactive sites 140, 152
 biochemical properties 127
 DNA interactions 139
 dose-determining parameter
 in vitro experiments 122–124
 in vivo tissue response models
 125–126
 oxygen consumption model 125
 drug development 127
 energy transfers 118
 high quantum energy 127
 immune response 131
 and immunology 126
 light propagation properties 118
 long wavelength activation 128–129
 photo-stability 128
 photon absorption 118
 photophysical and photochemical
 deactivation pathways 119
 radical production 120
 ROS generation 119
 singlet oxygen production 120
 subcellular localization 130–131
 supramolecular complex 142–143
 thermal effects 127
 type I/II photochemical reactions 119
- photolabile Ru-L coordination bond 92
- photosynthesis and solar fuels 46–47
- photosystem I (PSI) 46
- photosystem II (PSII) 46
- photovasoelaxation 265–268
- phthalocyanine-macrocyclic-containing
 [FeFe] Hase model 83
- “piano-stool” complexes 242, 282
- poly-3,4-ethylenedioxythiophene/
 poly-styrenesulfonate
 (PEDOT/PSS) nanocomposite 77
- polyoxometalates (POMs) 57–60
- polypyridyl ligands 9
- polypyridyl ruthenium(II) complexes 68
- proton coupled electron transfer (PCET)
 49
- pUC18 DNA 97, 144, 147–149
- pyridine 305–306
- 2-pyridinephenyl 171
- Q**
- Q-absorption band 128
- quinolone 305–306
- R**
- RAPTA-C 169, 283
- Ru(II) species 31
- [Ru^{IV}₄(μ-O)₄(μ-OH)₂(H₂O)₄(γ-SiW₁₀O₃₆)₂]¹⁰⁻ 59
- [Ru(bda)pic₂] dimer 58
- [Ru(bpy)₃]Cl₂ 72
- [Ru(bpy)₃]²⁺ cation sensitized H₂
 photoproduction 82
- [Ru(bpy)₂(L-pyr)Co(dmgH)₂(Cl)]²⁺ 72
- [Ru(bpy)₂(L-pyr)Co(dpgBF₂)₂(OH₂)]²⁺
 72
- [[Ru(bpy)₂(phen-NH₂)]²⁺ 81
- Ru(bpy)₂(L-pyr)Co(dmgBF₂)₂(OH₂)]²⁺
 72
- [RuCl(L1.2)(H₂O)₂] 299
- [Ru₃(CO)₁₂] trimer 30
- Ru-Hbpp catalyst 54–55
- [Ru(L1.1)₃] 299
- RuP/CoPmodified TiO₂ 75
- Ru(phen)₂(L-pyr)Co(dmgBF₂)₂(OH₂)]²⁺
 72
- Ru photophysics 100, 105
- Ru(tpy)(tpp)](PF₆)₂ 14
- RuO₄ 37
- ruthenium (0) and (-2) 29–30
- ruthenium(I) 29
- ruthenium(II) 31–34
 photosensitizers 84
 phythalocyanine macrocycles 82
 polypyridyl complexes (RPCs)

- ruthenium(II) (*contd.*)
 anticancer therapeutics 232–234
 biological application 225
 intracellular DNA 226
 MLCT luminescence 226
 Raman microscopy 231
 ruthenium(III) 34–35
 KP1019/NKP-1339 276, 281
 NAMI-A 273–276
 structural formulas 272
 ruthenium(IV), ruthenium(V), and
 ruthenium(VII) 36–37
 ruthenium(VIII) 37
 ruthenium-and cobalt-containing
 complexes for hydrogen production
 bridged systems 70–77
 hydrogenases, with ruthenium(II)
 complexes 77–84
 nonbridged systems 68–69
- S**
- Sadler-type compounds 283
 Schiff bases 307–309
 single site Ru-WOCs 55–56
 [(SiP^{*ipr*}₃)Ru(N₂)] 30
 size exclusion chromatography-inductively
 coupled plasma mass spectrometry
 (SEC-ICP/MS) 165
 sodium-dependent multivitamin
 transporter (SMVT) system 171
 species jump 293
 stereochemistry and common oxidation
 states
 alkenes and alkynes 26
 anhydrous binary oxides 26
 chemistry of ruthenium(II) and (III)
 31–36
 higher oxidation states of ruthenium
 36–37
 redox processes 26
 ruthenium in low oxidation states
 27–30
 substitution reactions of ruthenium(II)
 and (III) 36
 supramolecular complex 155
 DNA photomodification agents
 142–143
- t**
- 2,2':6',2''-terpyridine 305–306
 thioredoxin reductase (TrxR) 207
 2,3,5,6-tetrakis(2-pyridyl)pyrazine 14, 15
 (tpy)Ru(tpp)IrCl₃](PF₆)₂ 14
 trans-plasma membrane electron
 transport (tPMET) systems 209
 transmission electron microscopy (TEM)
 231
 tridentate 307–309
 triplet-triplet annihilation upconversion
 105–106
 tris(2,2'-bipyridine)ruthenium(II)-
 cobalt(II) macrocycle system 69
 tumor targeting mediated by plasma
 proteins 276–277
 two-photon absorption (TPA)
 photosubstitution 109–110
- u**
- upconverting nanoparticles (UCNP)
 106, 108
- v**
- Vanadium 151–152, 201
 vascular endothelial growth factor 207
 Virginia Tech 15–16
- w**
- Warburg effect 209
 Washington State University 13–15
 water oxidation catalysis
 artificial water oxidation 49–50
 heptacoordinated Ru intermediates
 56–57
 Meyer's blue dimer 53–54
 polyoxometalates 57–60
 Ru-Hbpp catalyst 54–55
 ruthenium oxide 50–52
 SC/P/WOC components 61
 single site Ru-WOCs 55–56
 solar energy conversion 60
- Z**
- zero valent ruthenium–cobalt
 (Ru–Co)-based nanocluster 76